Genprex on path to receive European patent for Reqorsa in cancer

Genprex (GNPX) announced that the European Patent Office has communicated its intent to grant Genprex a patent for the use of Reqorsa Gene Therapy in combination with PD-1 antibodies for the treatment of cancer. This patent will expand on the previously granted patents for Reqorsa in combination with PD-1 antibodies, which have been granted in the U.S., Japan, Mexico, Russia, Australia, Chile, China, and Singapore. Reqorsa is initially being developed in combination with prominent, approved cancer drugs to treat lung cancer. In preclinical studies, The company believes Reqorsa’s attributes position it to provide potential treatments that improve on these current therapies for patients with lung cancer and possibly other cancers.